Efficacy and Safety of 0.01% and 0.02% Atropine for the Treatment of Pediatric Myopia Progression Over 3 Years


Tags CGMHOPH Pediatric Refraction
Journal JAMA Ophthalmology
Status 審查完成
校稿者 蕭靜熹 醫師

JAMA Ophthalmology Published online June 1, 2023




  • 該研究納入了576名參與者,並將其隨機分配到治療組。
  • 主要療效結果是在36個月時近視進展小於0.50屈光度的參與者比例。
  • 低劑量阿托品,具體濃度為0.01%和0.02%,與安慰劑進行比較。
  • 在36個月時,與安慰劑相比,低劑量阿托品0.01%顯著增加了反應者(近視進展較少的參與者)的比例,並減緩了球面等效屈光(SER)進展和軸向伸長(眼睛的加長)。
  • 低劑量阿托品0.02%在減緩軸向伸長方面具有益處,但並未顯著增加反應者比例或減緩SER進展。
  • 安全評估顯示,這兩種低劑量阿托品濃度都是安全且耐受良好的。
  • 研究結論是,特別是0.01%濃度的低劑量阿托品可能為兒童近視進展提供一種治療選擇。


English Abstract

Place English abstract here

The study aimed to evaluate the efficacy and safety of low-dose atropine eye drops in slowing the progression of myopia (nearsightedness) in children.

Here are the key findings mentioned in the excerpt:

  • The study included 576 participants who were randomly assigned to treatment groups.
  • The primary efficacy outcome was the proportion of participants with less than 0.50 diopters of myopia progression at month 36.
  • Low-dose atropine, specifically at concentrations of 0.01% and 0.02%, was compared with a placebo.
  • At month 36, compared to the placebo, low-dose atropine 0.01% significantly increased the proportion of responders (participants with less myopia progression) and slowed mean spherical equivalent refractive (SER) progression and axial elongation (lengthening of the eye).
  • Low-dose atropine 0.02% showed benefit in slowing axial elongation but did not significantly increase the proportion of responders or slow SER progression.
  • Safety assessments indicated that both low-dose atropine concentrations were safe and well-tolerated.
  • The authors concluded that low-dose atropine, particularly at a concentration of 0.01%, may provide a treatment option for childhood myopia progression.

It’s important to note that this is only a small portion of the full research article, and the findings should be interpreted in the context of the complete study. For more detailed information and a comprehensive understanding of the research, it is recommended to read the full article.